Despite numerous advances in the management of heart failure, hospital admission and readmission rates remain high with patients requiring complex, coordinated care. The goal of this activity is to help cardiologists and other healthcare professionals improve clinical outcomes in their patients with heart failure. The roundtable discussion will focus on the identification and classification of heart failure, the integration of current evidence-based recommendations, and the optimization of pharmacologic therapies for patients with heart failure in order to reduce admission rates and improve patient health outcomes.
This patient case will illustrate the key aspects of guideline-based management strategies for individuals with heart failure with reduced ejection fraction (HFrEF)
Heart failure (HF) affects 5.7 million men and women in the United States, with 915,000 new cases occurring annually and a resultant 1,000,000 hospitalizations, which translates into an annual estimated cost of over $30 billion dollars. Mortality with this condition is high, approximately 50% at five years. Implementation of the advances in management of heart failure have the potential to improve patients' quality of life, reduce the need for hospitalizations, reduce total medical costs, and prolong survival. This lecture will review the current evidence-based, guideline recommended diagnosis and management of heart failure. The essential roles of evidence-based heart failure medications, device therapy, patient education, and disease management will be discussed.
Heart failure is the inability of the heart to generate sufficient cardiac output to meet the metabolic demands of the end organs, or to do so only with increased cardiac filling pressures. In this session, you will learn to evaluate patients with new or worsening heart failure, design evidence-based treatment plans based on its stages and phenotypes, and refer patients to cardiovascular/heart disease specialists when appropriate.
Despite significant advances in heart failure management, including pharmacotherapy and devices, treating this complex condition remains challenging. This activity discusses the differences in pathophysiology of heart failure with reduced and preserved ejection fraction and the different treatment approaches required for each condition. Novel agents under investigation that hold promise for treatment of this population are also discussed.
Heart failure (HF) affects over 5 million Americans, with 825,000 new cases occurring annually and a resultant 1,000,000 hospitalizations, which translates into an annual estimated cost of over $30 billion dollars. Implementation of the advances in management of heart failure have the potential to improve patients' quality of life, reduce the need for hospitalizations, reduce total medical costs, and prolong survival. This activity will review the current evidence-based, guideline recommended diagnosis and management of heart failure. Dr. Fonarow, a leading expert in Cardiovascular Medicine will discuss the essential roles of evidence-based heart failure medications, device therapy, patient education, and disease management.
In this case, Dr. Shah will highlight some tenets of treating heart failure including how to assess and treat the disease based on guidelines.
In this activity, Dr. Anderson answers some common questions encountered by primary care physicians in the management and care of patients with heart failure. Some of the topics discussed include the use of cardiac MRI, appropriate use of biomarkers and the recommended drugs to be used in patients with heart failure.
This session reviews some challenging diagnostic cases faced in clinical practice. Cases feature interpretation of abnormal labs and screening reports in addition to encounters with common conditions responsible for hospital admissions.
This session will review a number of clinically relevant trials/topics recently presented at the American College of Cardiology Scientific Sessions in March 2017, including updates in the management of patients with hypercholesterolemia, heart failure, valvular heart disease, arrhythmias, and more.